<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; assembly</title>
	<atom:link href="http://www.tapanray.in/tag/assembly/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma and Climate Change: The Unseen Reckoning</title>
		<link>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-and-climate-change-the-unseen-reckoning</link>
		<comments>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/#comments</comments>
		<pubDate>Thu, 02 Oct 2025 12:09:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Climate change]]></category>
		<category><![CDATA[Donald]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharma CEO]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[UN]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10975</guid>
		<description><![CDATA[When the U.S. President Donald Trump addressed the UN General Assembly in September 2025, his remarks on climate change were strikingly dismissive. While global leaders urged urgent action, Trump doubled down, calling climate concerns “a con job” and questioning the &#8230; <a href="http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India Being World’s Third largest Covid Vaccine Maker: Will All Indians Benefit?</title>
		<link>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit</link>
		<comments>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/#comments</comments>
		<pubDate>Mon, 02 Nov 2020 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[all third]]></category>
		<category><![CDATA[ambiguity]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[Bihar]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[countrywide]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[election]]></category>
		<category><![CDATA[equitable]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indians]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[maker]]></category>
		<category><![CDATA[manufacturer]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Nationalism]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Serum Institute of India]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uninterrupted]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[virus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10311</guid>
		<description><![CDATA[Apprehensions on the time of availability notwithstanding, equitable access to Covid vaccines for all, remain the best hope to leash the deadly virus, as the pandemic overwhelms the world. According to the World Health Organization (WHO) ‘Coronavirus Update 37’ of October 06, &#8230; <a href="http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Self-made Barriers To Business Transparency Impacting Drug Access</title>
		<link>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=self-made-barriers-to-business-transparency-impacting-drug-access</link>
		<comments>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/#comments</comments>
		<pubDate>Mon, 05 Aug 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[72nd]]></category>
		<category><![CDATA[AMF]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Geneva]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[impact access]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orginal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resolution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[WHA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9655</guid>
		<description><![CDATA[A recently published book on pharma industry tried to expose the deceit behind many generic-drug manufacturing—and the consequent risks to global health. This publication is described as an ‘explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers &#8230; <a href="http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health Care in India And ‘Development For All’ Intent</title>
		<link>http://www.tapanray.in/health-care-in-india-and-development-for-all-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=health-care-in-india-and-development-for-all-intent</link>
		<comments>http://www.tapanray.in/health-care-in-india-and-development-for-all-intent/#comments</comments>
		<pubDate>Sun, 24 Dec 2017 23:46:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[December]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[elections]]></category>
		<category><![CDATA[Gujarat]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manifesto]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8706</guid>
		<description><![CDATA[‘Development for All’ has become a buzzword, especially in the political arena of India, and is being used frequently during all recent elections as no one can deny its crucial importance in a country like ours. Nonetheless, some do feel &#8230; <a href="http://www.tapanray.in/health-care-in-india-and-development-for-all-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/health-care-in-india-and-development-for-all-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Big Pharma&#8217; Prowls Falter: Triggers Off Yet Another Critical Debate</title>
		<link>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-prowls-falter-triggers-off-yet-another-critical-debate</link>
		<comments>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/#comments</comments>
		<pubDate>Mon, 25 Nov 2013 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[council. India]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pitroda]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sam]]></category>
		<category><![CDATA[SME]]></category>
		<category><![CDATA[sparks]]></category>
		<category><![CDATA[stricter]]></category>
		<category><![CDATA[stumbles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[triggers]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Wharton]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3101</guid>
		<description><![CDATA[The &#8216;Big Pharma&#8217; prowls faltered yet again exposing the ‘fault line’ to all, when the GSK global head honcho, a pharma icon in his own right, Sir Andrew Witty supported the pharmaceutical policy of India, while in the country earlier &#8230; <a href="http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
